Maternal Transport and Health Outcomes: Clinical Insights and Evidence-Based Strategies

Abstract

Maternal transport refers to the timely transfer of pregnant individuals from lower-level healthcare facilities to centers equipped with advanced maternal and neonatal care, aiming to optimize outcomes for both mother and infant. This review evaluates the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, and recent advances in maternal transport. Drawing on recent evidence and current guidelines, this article provides a comprehensive overview for clinicians, highlighting the mechanisms by which maternal transport impacts health outcomes, identifying gaps in care, and offering practical recommendations for optimizing perinatal safety.

Introduction

Maternal transport plays a pivotal role in modern perinatal care, ensuring that high-risk pregnancies and acute maternal complications are managed in settings with appropriate resources and expertise. The process entails clinical assessment, stabilization, and safe conveyance of pregnant individuals to referral centers, often under time-sensitive conditions. Given the persistent disparities in maternal and neonatal outcomes globally, optimizing maternal transport systems is essential for reducing preventable morbidity and mortality. This article synthesizes recent research and clinical guidelines to inform best practices in maternal transport.

Epidemiology / Disease Burden

Globally, maternal mortality rates remain unacceptably high, with the World Health Organization estimating approximately 295,000 maternal deaths annually as of 2017. In high-income countries, severe maternal morbidity is a growing concern, with conditions such as preeclampsia, eclampsia, postpartum hemorrhage, and sepsis accounting for the majority of life-threatening complications. The incidence of maternal transport varies by region and healthcare infrastructure, but studies have consistently shown that timely referral and transport to tertiary centers significantly reduce adverse maternal and neonatal outcomes. For example, in the United States, interfacility maternal transport is required in 2–7 per 1,000 deliveries, with higher rates in rural and resource-limited settings.

Pathophysiology

The underlying pathophysiology necessitating maternal transport typically involves acute decompensation or anticipated risk of deterioration that cannot be managed at the originating facility. Common scenarios include progressive preeclampsia leading to multi-organ dysfunction, obstetric hemorrhage resulting in hypovolemic shock, or preterm labor with imminent delivery prior to fetal viability. These conditions require timely intervention, advanced monitoring, and multidisciplinary care, which may not be available at all healthcare institutions. The physiologic changes of pregnancy such as increased blood volume, altered coagulation, and cardiovascular adaptations render pregnant individuals uniquely vulnerable to rapid deterioration, underscoring the need for specialized care during transport.

Risk Factors

Multiple risk factors increase the likelihood of maternal transport, including maternal age extremes, pre-existing medical conditions (e.g., hypertension, diabetes, cardiac disease), multiple gestation, placental abnormalities, and a history of prior obstetric complications. Socioeconomic status, geographic barriers, and limited access to prenatal care are additional contributors, particularly in rural and underserved areas. Facility-level factors, such as lack of advanced obstetric services or neonatal intensive care units (NICU), also necessitate transfer. Recognizing and stratifying these risks early is critical for prompt identification of patients who may benefit from transport.

Clinical Features

Patients requiring maternal transport often present with signs and symptoms indicative of impending or ongoing obstetric emergencies. These may include severe hypertension, persistent headache, visual disturbances, right upper quadrant pain (suggestive of HELLP syndrome), vaginal bleeding, uterine tenderness, preterm contractions, or evidence of fetal compromise (e.g., non-reassuring fetal heart rate tracings). Rapid clinical deterioration may also manifest as altered mental status, respiratory distress, or hemodynamic instability. Early recognition of these features allows for timely intervention and coordination of transport.

Diagnosis

Diagnostic evaluation prior to and during maternal transport focuses on identifying the underlying etiology, assessing severity, and monitoring for complications. Laboratory studies may include complete blood count, coagulation profile, liver and renal function tests, and urinalysis for proteinuria. Point-of-care ultrasound is invaluable for assessing fetal well-being, placental location, and amniotic fluid volume. Continuous fetal and maternal monitoring with cardiotocography and vital signs is essential. Communication between referring and receiving facilities is critical for ensuring that diagnostic data are accurately relayed and that appropriate interventions continue en route.

Treatment & Management

Stabilization prior to transport is paramount and should include airway management, hemodynamic support, seizure prophylaxis (e.g., magnesium sulfate for preeclampsia/eclampsia), transfusion for hemorrhage, and tocolytics for preterm labor when indicated. Intravenous access, oxygen supplementation, and administration of corticosteroids for fetal lung maturity may be required. Transport teams must be trained in obstetric emergencies and equipped with protocols for managing acute decompensation during transit. Coordination between referring physicians, transport personnel, and receiving specialists facilitates seamless transitions and continuity of care.

Recent Advances / Emerging Therapies

Recent advances in maternal transport include the implementation of telemedicine consultations, enhanced triage algorithms, and the use of mobile health applications to expedite referrals. Simulation-based training for transport teams has shown promise in improving preparedness and reducing adverse events. Additionally, integration of perinatal regionalization networks and standardized transport protocols have been associated with improved maternal and neonatal outcomes. Emerging therapies, such as novel uterotonic agents and noninvasive fetal monitoring technologies, are being evaluated for their potential to further optimize management during transport.

Guideline Recommendations

Current guidelines from organizations such as the American College of Obstetricians and Gynecologists (ACOG), Society for Maternal-Fetal Medicine (SMFM), and the Royal College of Obstetricians and Gynaecologists (RCOG) emphasize early risk identification, pre-transport stabilization, and coordinated multidisciplinary communication. Recommendations include standardized criteria for referral, protocols for stabilization, and regular audit of transport outcomes. Facilities should maintain readiness with trained personnel, equipment, and protocols to ensure safe and timely transport of high-risk mothers and fetuses.

Conclusion

Maternal transport is a critical component of perinatal care systems, directly influencing maternal and neonatal morbidity and mortality. Evidence supports that timely, well-coordinated transport, guided by current best practices and multidisciplinary collaboration, leads to improved outcomes. Continued investment in regionalized care networks, staff training, and emerging technologies will further enhance the safety and effectiveness of maternal transport. Clinicians must remain vigilant in identifying candidates for transport and ensuring adherence to evolving guidelines to optimize health outcomes for mothers and infants.